Back to search
FDAFDA · Food and drugs·Recall number D-0575-2023

Admelog, insulin lispro injection, 100 units/mL (U-100), 3mL multi-dose vial, Rx Only, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 A Sanofi Company. NDC 0024-5926-05

Published May 24, 2023 · Recall initiated: April 11, 2023

Summary

FDA records drug Class II recall D-0575-2023, published May 24, 2023 and initiated April 11, 2023. Recalling firm: Sanofi-Aventis U.S. LLC; Status: Ongoing; Reported quantity: 51,325 vials; Lot: Lot # 3F497B, EXP 12-31-2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Malformed crimped collar seal

What to do

Voluntary: Firm initiated · E-Mail

Get an email if ADMELOG has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ADMELOG
Manufacturer
Sanofi-Aventis U.S. LLC
Distributor
Nationwide in the USA
Lot
Lot # 3F497B, EXP 12-31-2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Admelog, insulin lispro injection, 100 units/mL (U-100), 3mL multi-dose vial, Rx Only, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 A Sanofi Company. NDC 0024-5926-05 recalled?

Yes. FDA published recall D-0575-2023 on May 24, 2023. Reported hazard: Lack of Assurance of Sterility: Malformed crimped collar seal

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ADMELOG.